array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Tekla Life Sciences Investors" ["slug"]=> string(38) "30be8-us-tekla-life-sciences-investors" ["logo"]=> NULL ["description"]=> string(523) "Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund that primarily invests in the life sciences industry. The fund aims to provide long-term capital appreciation through investments in companies in the life sciences industry with potential for above-average long-term growth. It focuses on smaller, emerging companies and may invest up to 40% of its assets in restricted securities of both public and private companies. The fund is traded on the New York Stock Exchange under the ticker HQL." ["address_street"]=> string(17) "2 Liberty Sq FL 9" ["address_place"]=> string(6) "Boston" ["address_region"]=> string(13) "Massachusetts" ["founding_date"]=> string(10) "2000-01-26" ["website_domain"]=> string(12) "teklacap.com" ["website_url"]=> string(24) "https://www.teklacap.com" ["industry_codes"]=> array(1) { [0]=> string(39) "Management Investment Offices, Open-End" } ["employee_count"]=> int(7) ["article_count"]=> int(78) } ["articles"]=> array(2) { [0]=> array(7) { ["title_en"]=> string(72) "Johnson & Johnson (NYSE:JNJ) Shares Bought by RNC Capital Management LLC" ["snippet_en"]=> string(217) "RNC Capital Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)." ["url"]=> string(112) "https://www.defenseworld.net/2023/10/09/johnson-johnson-nysejnj-shares-bought-by-rnc-capital-management-llc.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/541f0636-9fd8-491d-8e1a-8da06ab1b9dc" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-10-09" ["categories"]=> array(9) { [0]=> string(14) "Issuing Shares" [1]=> string(11) "Regulations" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(24) "Quarterly/Annual Figures" [4]=> string(11) "Acquisition" [5]=> string(18) "Expansion & Growth" [6]=> string(16) "Share Repurchase" [7]=> string(18) "General Investment" [8]=> string(12) "Stock Market" } } [1]=> array(7) { ["title_en"]=> string(82) "Lbmc Investment Advisors LLC Acquires 1,287 Shares of Johnson & Johnson (NYSE:JNJ)" ["snippet_en"]=> string(300) "Lbmc Investment Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,294 shares of the company's stock after purchasing an additional 1,287 s" ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-jnj-sec-filing-2023-09-29/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/28564341-88d3-4b88-b2ed-9009ed96617e" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-09-29" ["categories"]=> array(10) { [0]=> string(14) "Issuing Shares" [1]=> string(11) "Regulations" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(24) "Quarterly/Annual Figures" [4]=> string(11) "Acquisition" [5]=> string(24) "Stock Research & Ratings" [6]=> string(16) "Share Repurchase" [7]=> string(18) "General Investment" [8]=> string(19) "Investment Requests" [9]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(22) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(16) } [1]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(6) } [2]=> array(2) { ["name"]=> string(10) "Tax Havens" ["count"]=> int(6) } [3]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(5) } [4]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(4) } [5]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(4) } [6]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(4) } [7]=> array(2) { ["name"]=> string(16) "Share Repurchase" ["count"]=> int(4) } [8]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(3) } [9]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [11]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(2) } [12]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(2) } [13]=> array(2) { ["name"]=> string(22) "Business Restructuring" ["count"]=> int(2) } [14]=> array(2) { ["name"]=> string(20) "Corporate Governance" ["count"]=> int(2) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(23) "Supply Chain Management" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(19) "Investment Requests" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(1) } } } 30be8-us-tekla-life-sciences-investors